Anumana announced today that it brought its diagnostic ECG-AI technology into perioperative and acute cardiac care with help from Boston Scientific.
Anumana expands AI cardiac care platform with support from Boston Scientific
Related Articles
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases CAMBRIDGE, Mass. – June 25, 2024 – Anumana, a leading AI-driven health…June 25, 2024
Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help…December 16, 2022
Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction
Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failureOctober 02, 2023
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022